ValiRx plc - Asset Resilience Ratio

Latest as of June 2002: 6.92%

ValiRx plc (VAL) has an Asset Resilience Ratio of 6.92% as of June 2002. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ValiRx plc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

£241.00K

≈ $323.64K USD Cash + Short-term Investments

Total Assets

£3.48 Million

≈ $4.68 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2001–2017)

This chart shows how ValiRx plc's Asset Resilience Ratio has changed over time. See VAL equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down ValiRx plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VAL company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	£0.00	0%
Short-term Investments	£241.00K	6.92%
Total Liquid Assets	£241.00K	6.92%

Asset Resilience Insights

Limited Liquidity: ValiRx plc maintains only 6.92% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ValiRx plc Industry Peers by Asset Resilience Ratio

Compare ValiRx plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for ValiRx plc (2001–2017)

The table below shows the annual Asset Resilience Ratio data for ValiRx plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2017-12-31	2.37%	£117.23K ≈ $157.43K	£4.94 Million ≈ $6.63 Million	-0.46pp
2016-12-31	2.84%	£140.68K ≈ $188.91K	£4.96 Million ≈ $6.66 Million	-25.73pp
2015-12-31	28.57%	£1.46 Million ≈ $1.96 Million	£5.12 Million ≈ $6.88 Million	+2.19pp
2001-12-31	26.38%	£425.00K ≈ $570.74K	£1.61 Million ≈ $2.16 Million	--

pp = percentage points

About ValiRx plc

LSE:VAL UK Biotechnology

Market Cap

$184.52 Million

£137.40 Million GBP

Market Cap Rank

#29436 Global

#581 in UK

Share Price

£0.19

Change (1 day)

+0.00%

52-Week Range

£0.18 - £0.75

All Time High

£3312.50